tbuckley/cabot-search huggingface dataset:
FRI0722-HPR Postural problems and pain in patients with juvenile idiopathic arthritis
Authors: E. Tarakci, N. Arman, S. Sahin, A. Adrovic, K. Barut, O. Kasapcopur
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Juvenile idiopathic arthritis (JIA) is a chronic autoimmune condition of unknown etiology. JIA combine with joint pain and inflammation that affects children who are less 16 years of age and continue more 6 weeks. JIA is a chronic inflammatory disease resulting in joints arthritis, pain and deformities. Disturbances in the posture may occur before deformities in patients with JIA. In some cases, pain can also lead to postural deterioration. Postural control is the ability to maintain equilibrium in a gravitational field by keeping or returning the center of body mass over its base of support. <h3>Objectives:</h3> The first purposes of this study was to assessed postural problems in patients with JIA and compared with healthy peers. The other objective was to examine the pain relationship with postural problems. <h3>Methods:</h3> 19 patients with JIA aged 5–17 years (13 girls and 6boys) diagnosed according to ILAR classification criteria and 19 healthy controls were enrolled in this cross-sectional study. "PostureScreen Mobile®" was used to evaluate static posture, "11-point Numeric Analogue Scale (NRS)" was used to evaluate the pain (during rest, activity and exercise). The PostureScreen Mobile® an application facilitates the assessment of posture in a variety of settings. Anterior (Head, Shoulders, Ribcage, Hips) and lateral translation (Head, Shoulders, Hips, Knees) were recorded and calculated as a total score for anterior and lateral. For statistical analysis SPSS Version 21.0 program was used. <h3>Results:</h3> The mean age and body mass index of patients and healthy control were 10.79±3.59 and 10.68±2.86 years, 17.05±3.88, and 18.50±2.49 kg/m<sup>2</sup>, respectively. The mean of NRS-rest, activity and exercise scores were 1.18±1.42, 3±2.64 and 1.91±2.02, respectively. As a result of postural assessment for patients and healthy control, the mean of anterior translation scores was significantly higher in patients with JIA than healthy control (p=0.014) (table 1). Two significant correlations with NRS-rest between hip anterior translation (r=0.375, p=0.029) and ribcage anterior translation (r=-0.534, p=0.027) were found. <h3>Conclusions:</h3> We found that children with JIA have minimal postural problems according to their healthy peers. At the same time, pain during rest is associated with anterior postural deterioration. Therefore in future researches, translations in the posture should be evaluated comprehensively in children with JIA for larger sample size. If it is not intervened in the early period, it may lead to overloading of joints and increased pain in later periods. <h3>Disclosure of Interest:</h3> None declared
Gordon Edyvean Heard
Authors: Malcolm H Wheeler
Journal: BMJ (2019)

The art and science of surgery were never more effectively demonstrated than as seen in the clinical practice of the Cardiff vascular surgeon, Gordon Edyvean Heard. In the 1960s vascular surgery was still in the early stages of development. The major arteries of the body can be diseased with atherosclerosis and other intrinsic defects resulting in dilatation (aneurysm) or blockage. Unblocking and repair or replacement of arteries became possible with the development of new surgical techniques and the development of methods for replacing damaged blood vessels.

Rupture of an aneurysm of the major aortic artery, either in the chest or, more commonly, in the abdomen, is a life threatening emergency requiring prompt surgical intervention. In the UK, one in 25 men between the ages of 65 and 75 have an abdominal aortic aneurysm, with rupture causing 6000 deaths each year.

Heard was at the forefront of the development of this new vascular surgical specialty. He brought to it great surgical expertise for those patients who came to Cardiff, but he recognised that in the large, sparsely populated area of Wales there needed to be immediately available local services. Every hospital in Wales could not have a dedicated vascular surgeon but he ensured that in every major district there was a general surgeon whom he had trained to provide immediate and lifesaving care. There is no doubt that many patients throughout the principality owed their lives to Gordon Heard’s superb teaching and training of junior staff.

Gordon Heard was born on 23 February 1926 in Rhiwbina, Cardiff, the second son of a geologist at Cardiff University. Several particular events in his life may have been influential in his determination and ability to become a surgeon. In 1939, at the age of 13 and at the outbreak of the war, he became …
AB0987 Frequency of utilisation of the central dxa bone densitometry in patients with multiple sclerosis
Authors: A.N. Klimo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Multiple sclerosis patients can have a higher risk from occurrence of osteoporosis. Reduced bone mass density can be related to a cumulative effect of different factors, most common ones being physical inactivity, reduced intake of vitamin D and use of medications such as glucocorticoids. <h3>Objectives</h3> The aim of this research was to explore the level of awareness in patients and physicians on the significance of the utilisation of DXA bone densitometry in patients with multiple sclerosis. <h3>Methods</h3> The observational analytical cross-section study included 366 multiple sclerosis patients on stationary treatment at the Special rehabilitation hospital "Banja Kanjiža" in Kanjiža in the period between 2013 and 2017. The following parameters were observed in patients: sex, age, duration and form of basic disease, the level on the Kurtzke Expanded Disability Status Scale, utilisation of glucocorticoids, occurrence of pathological fractures and intake of vitamin D, i.e. of medication for the treatment of osteoporosis in order to determine their impact on the frequency of the low bone mineral density (BMD). Statistical data processing and analysis was conducted in the SPSS ver 20.0 program by IBM corporation. <h3>Results</h3> In the period in question, an average of 128 multiple sclerosis patients were treated, out of those 62.3% (n=228) with relapsing-remitting type of disease, and n=366 first time patients. Within the given period, 36% more women than men were rehabilitated (f=249 vs. m=117). During the five-year long period of observation of said patients, only 8.5% (n=31) of patients with different levels of bone metabolic disorders established underwent central DXA bone densitometry. Pathological fracture on a small trauma was suffered in 6.8% (n=25) patients. Of the abovementioned parameters, only the female sex (X<sup>2</sup>=84.492; p&lt;0.001) and age (t=2.100; p=0.036) statistically significantly influenced the occurrence of low bone mineral density. <h3>Conclusions</h3> It is necessary to increase the level of health education of multiple sclerosis patients on the consequences of low bone mineral density. The highest risk of osteoporotic fracture is in older women suffering from multiple sclerosis. <h3>Disclosure of Interest</h3> None declared
Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer
Authors: Chao Lin, Hongyong He, Hao Liu, Ruochen Li, Yifan Chen, Yangyang Qi, Qi Jiang, Lingli Chen, Peipei Zhang, Heng Zhang, He Li, Weijuan Zhang, Yihong Sun, Jiejie Xu
Journal: Gut (2019)

Objective Our previous studies have identified CXCL8 as the crucial chemokine responsible for gastric cancer metastasis mediated by loss of RACK1. However, the regulatory effect of CXCL8 on immune surveillance in gastric cancer remains obscure. Design Flow cytometry analyses were performed to examine major source of CXCL8 and phenotypes of immune cells in fresh tumour tissues from 76 patients with gastric cancer. Real-time PCR was performed to analyse CXCL8 mRNA level in gastric cancer tissues. For immunohistochemical analyses, a total of 420 patients with gastric cancer undergoing curative resection were enrolled. In vitro culture of fresh tumour tissue was performed to evaluate the potential therapeutic effect of blocking CXCL8 pathway in gastric cancer. Results Increased level of CXCL8 indicates poor clinical outcome and tumour progression in patients with gastric cancer. In gastric cancer tissues, CXCL8 is predominantly secreted by macrophages and colony stimulating factor 2 (CSF-2) facilitates macrophage-derived CXCL8 secretion. High level of CXCL8 is associated with decreased CD8 + T cells infiltration and Ki67 + CD8 + T cells proportion. Moreover, CXCL8 also inhibits CD8 + T cells function by inducing the expression of PD-L1 on macrophages. Finally, we show that a small-molecule CXCR2 inhibitor, reparixin, drives the decreased programmed death-ligand 1 (PD-L1 + ) macrophages and promotes antitumour immunity. Accordingly, high levels of CXCL8 + macrophages are positively correlated with poor prognosis in patients with gastric cancer. Conclusions CXCL8 is predominantly secreted by macrophages and contributes to the immunosuppressive microenvironment by inducing PD-L1 + macrophages in gastric cancer. CXCL8 inhibitors may drive antitumour response, providing potential therapeutic effects for patients with gastric cancer.
THU0646 Evaluating the quality of care for rheumatoid arthritis
Authors: C. Barber, D. Marshall, E. Szefer, D. Thompson, D. Lacaille
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The Arthritis Alliance of Canada (AAC) has developed performance measures (PMs) to evaluate RA care quality. <h3>Objectives</h3> To operationalize and report on 4 PMs using administrative data for British Columbia (BC), Canada: PM1) percentage of patients with new onset RA with at least one visit to a rheumatologist in the first year after diagnosis, PM2) percentage of RA patients under the care of a rheumatologist seen in follow-up at least once per year, PM3) percentage of RA patients dispensed a disease modifying anti-rheumatic drug (DMARD) during the measurement year, PM4) time to DMARD therapy in new onset RA. <h3>Methods</h3> All patients with RA visits between 01/01/1997 and 31/12/2009 in BC were identified using health administrative data and followed until December 2014. Cases were identified by ≥2 physician billing codes for RA ≥8 weeks but ≤5 years apart. For this study, only cases age &gt;18 who were seen by a rheumatologist at some point over follow-up were included. PM1: The percentage of incident RA cases with at least one visit to a rheumatologist within one year of their first RA visit was evaluated. PM2: The proportion of prevalent RA cases having at least one visit per year was calculated for those under rheumatology care. PM3: The percentage of prevalent RA patients dispensed a DMARD (including biologic agents and small molecule inhibitors) was calculated. PM4: time from RA onset (defined as first RA visit) to DMARD therapy was reported (in the calendar year of RA incidence), using median and 90th percentile wait time, as well as the proportion meeting the benchmark of 14 days. <h3>Results</h3> The cohort included 18 976 incident and 29 639 prevalent RA cases. The percentage of patients seen by a rheumatologist within 1 year from RA diagnosis increased over time, while the percentage of RA patients under the care of a rheumatologist seen in yearly follow-up declined steadily overtime. Further analysis (data not shown) suggests this is due to having more people with longer follow-up in the latter years, and lost to follow-up increasing over time, rather than a true calendar year effect. The percentage of RA patients dispensed a DMARD was suboptimal (56%&gt;65%). Of note, patients were not necessarily seen by a rheumatologist during the measurement year. The median time to DMARD improved over time to 23 days in 2009, with roughly one third receiving a DMARD within the benchmark of 14 days. <h3>Conclusions</h3> The present study represents the first time the AAC's PMs have been tested in administrative data and highlights where the measures are being met and potential gaps in care which require further examination. <h3>Disclosure of Interest</h3> None declared
Utility of Diffusion-weighted Imaging to Decrease Unnecessary Biopsies Prompted by Breast MRI: A Trial of the ECOG-ACRIN Cancer Research Group (A6702)
Authors: Habib Rahbar, Zheng Zhang, Thomas L. Chenevert, Justin Romanoff, Averi E. Kitsch, Lucy G. Hanna, Sara M. Harvey, Linda Moy, Wendy B. DeMartini, Basak Dogan, Wei T. Yang, Lilian C. Wang, Bonnie N. Joe, Karen Y. Oh, Colleen H. Neal, Elizabeth S. McDonald, Mitchell D. Schnall, Constance D. Lehman, Christopher E. Comstock, Savannah C. Partridge
Journal: Clinical Cancer Research (2019)

Abstract Purpose: Conventional breast MRI is highly sensitive for cancer detection but prompts some false positives. We performed a prospective, multicenter study to determine whether apparent diffusion coefficients (ADCs) from diffusion-weighted imaging (DWI) can decrease MRI false positives. Experimental Design: A total of 107 women with MRI-detected BI-RADS 3, 4, or 5 lesions were enrolled from March 2014 to April 2015. ADCs were measured both centrally and at participating sites. ROC analysis was employed to assess diagnostic performance of centrally measured ADCs and identify optimal ADC thresholds to reduce unnecessary biopsies. Lesion reference standard was based on either definitive biopsy result or at least 337 days of follow-up after the initial MRI procedure. Results: Of 107 women enrolled, 67 patients (median age 49, range 24–75 years) with 81 lesions with confirmed reference standard (28 malignant, 53 benign) and evaluable DWI were analyzed. Sixty-seven of 81 lesions were BI-RADS 4 (n = 63) or 5 (n = 4) and recommended for biopsy. Malignancies exhibited lower mean in centrally measured ADCs (mm2/s) than benign lesions [1.21 × 10−3 vs.1.47 × 10−3; P &amp;lt; 0.0001; area under ROC curve = 0.75; 95% confidence interval (CI) 0.65–0.84]. In centralized analysis, application of an ADC threshold (1.53 × 10−3 mm2/s) lowered the biopsy rate by 20.9% (14/67; 95% CI, 11.2%–31.2%) without affecting sensitivity. Application of a more conservative threshold (1.68 × 10−3 mm2/s) to site-measured ADCs reduced the biopsy rate by 26.2% (16/61) but missed three cancers. Conclusions: DWI can reclassify a substantial fraction of suspicious breast MRI findings as benign and thereby decrease unnecessary biopsies. ADC thresholds identified in this trial should be validated in future phase III studies.
AB0345 Does iron deficiency contribute to fatigue of patients with rheumatoid arthritis without anaemia?
Authors: F. Vidal, A. Gillibert, M. Quillard, P. Fardellone, S. Pouplin, O. Vittecoq, T. Lequerré
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Iron deficiency (ID) without anaemia is a cause of fatigue, which is itself a recurring complaint of patients with rheumatoid arthritis (RA). <h3>Objectives</h3> The objective of the study was to determine the prevalence of ID in patients with RA without anaemia and to analyse the relationship between ID with fatigue, disease activity and depression. <h3>Methods</h3> This study included patients with RA according to the ACR/<sup>EULAR 2010</sup> classification criteria (American College of Rheumatology/European League Against Rheumatism) followed up in the Rheumatology Department of Rouen University Hospital and who had a haemoglobin &gt;12.5 g/dl. Patients were either from the single-centre monocentric longitudinal cohort or from the seventh visit of the VErA (Very Early Arthritis) High-Norman regional cohort. For each patient of the longitudinal cohort, DAS 28 ESR (Disease Activity Score – erythrocyte sedimentation rate) the FACIT – version 4 fatigue score (Functional Assessment of Chronic Illness Therapy) and a depression score (Hospital Anxiety and Depression Scale) were collected. Serum ferritin, transferrin, serum iron and saturation coefficient of transferrin were measured for each patient. ID was defined as serum ferritin &lt;50 µg/L. <h3>Results</h3> One hundred and forty-one patients were included in the longitudinal cohort (78.7% women, mean age 13.50±9.51 years, positive rheumatoid factor and anti-citrullinated peptide antibodies in 83.6% and 86.5% of patients) and 74 RA patients from the VERA cohort (70.3% women, mean disease duration 2.74±0.24 years). The prevalence of ID was 15.6% in the longitudinal cohort (n=22/141) and 14.9% in the VErA cohort (n=11/74). In the longitudinal cohort, there were no significant differences between ID patients and non-deficient patients in fatigue (mean FACIT of 27.80±12.4 vs. 32.3±12.0; p=0.14), disease activity (mean DAS 28 VS 2.85±1.38 vs. 2.96±1.48; p=0.74) and depression (mean HAD score 5.86±4.12 vs. 5.80±3.84; p not calculated). <h3>Conclusions</h3> The prevalence of ID without anaemia was similar between early and old RA and was similar to that of the general French adult population (15.5%).<sup>1</sup> ID does not appear to be a major cause of fatigue in RA and does not affect the activity of the disease. The search for an ID is of limited value in exploring fatigue of RA patients. <h3>Reference</h3> [1] Institut National de Veille Sanitaire. Etude Nationale Nutrition santé, ENNS 2006. <h3>Disclosure of Interest</h3> None declared
Fish Consumption During Pregnancy—Reply
Authors: Philip Spiller, Carolyn T. Bramante, Michael Landa
Journal: JAMA Pediatrics (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Comparing Bortezomib-Lenalidomide-Dexamethasone (VRd) with Carfilzomib-Lenalidomide-Dexamethasone (KRd) in the Patients with Newly Diagnosed Multiple Myeloma (NDMM) in Two Observational Studies
Authors: Bin Li, Kaili Ren, Lei Shen, Peijie Hou, Zhenqiang Su, Alessandra Di Bacco, Jin-Liern Hong, Aaron Galaznik, Ajeeta B Dash, Victoria Crossland, Paul Dolin, Sandor Szalma
Journal: Blood (2018)
SAT0180 Two-year consolidated safety data for abp 501 in patients with moderate to severe rheumatoid arthritis
Authors: E. Krishnan, N. Zhang, H. Wang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background:</h3> Biosimilars are expected to have similar long-term safety profiles as originator products. <h3>Objectives:</h3> To describe the consolidated, 2-year safety data on ABP 501, an approved biosimilar to adalimumab. <h3>Methods:</h3> We combined individual patient data from a 26-week randomized controlled head-to-head study (parent study) comparing ABP 501 with adalimumab (NCT01970475) and its 72-week open-label extension (OLE) study (NCT02114931) in which all patients received only ABP 501. Safety data were reported by exposure-adjusted incidence rate as the number of subjects with the specified adverse events *(AEs) per 100 person-years. AEs from the parent and OLE studies were summarized; for each category, patients were included only once based on the 1st event in that AE category. All comparisons were performed descriptively. <h3>Results:</h3> In the parent study, 264 patients received ABP 501 and 262 patients received adalimumab reference product (RP). Of these, 229 in the ABP 501 arm and 237 in the RP arm entered and were treated in the open-label extension study. The exposure-adjusted incidence rate for treatment-emergent AEs by treatment group are shown in the Table. <h3>Conclusions:</h3> Over the 2-year observation period, there were no meaningful differences in AEs between adalimumab reference product and ABP 501. <h3>Disclosure of Interest:</h3> E. Krishnan Shareholder of: Amgen Inc., Employee of: Amgen Inc., N. Zhang Shareholder of: Amgen Inc., Employee of: Amgen Inc., H. Wang Shareholder of: Amgen Inc., Employee of: Amgen Inc.
AB0862 Anterior thoracic fatty corner lesions are useful in axial spondyloarthritis (SPA) diagnosis—data from a multicenter back pain-mri cohort in hong kong
Authors: H.Y. Chung, S.W.R. Yiu, H.H.L. Tsang
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> A fatty corner lesion (FCL), as defined by fat infiltration at the vertebral corner in T1 Magnetic Resonance Imaging (MRI) sequence, has been reported to be useful in Spondyloarthritis (SpA) diagnosis. <h3>Objectives</h3> Our objective is to systematically evaluate the diagnostic utility of FCLs in a large, multicenter back pain-MRI cohort in Hong Kong. <h3>Methods</h3> Three hundred and one patients with back pain were recruited from 3 rheumatology centres. Clinical, biochemical and radiological parameters were collected and all patients underwent a whole spine and sacroiliac (SI) joints MRI. FCLs from C4 to L5 levels were scored. Results were compared to expert-diagnosed axial SpA to determine the usefulness of FCLs in disease diagnosis. <h3>Results</h3> Anterior FCLs of whole or thoracic spine were found to be useful in axial SpA diagnosis. (AUC 0.622; p=0.003, AUC 0.640; p=0.001 respectively) Applying FCLs to the Modified New York (MNY) criteria and Assessment of SpondyloArthritis international Society (ASAS) axial SpA criteria, a minimum of 5 FCLs at whole spine level had a sensitivity of 66.4% and 91.6%, specificity of 98.4% and 91.9% respectively. Applying a minimum of 3 FCLs at thoracic spine level to the MNY criteria and ASAS axial SpA criteria yielded a sensitivity of 68.5% and 92.0%, specificity of 95.2% and 93.5% respectively. Three FCLs improves both classification criteria. <h3>Conclusions</h3> FCLs are useful in axial SpA diagnosis. A minimum of 3FCLs at the thoracic level is useful for the disease diagnosis. <h3>Disclosure of Interest</h3> None declared